https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences RSS Feed for Journal of Pharmacy & Pharmaceutical Sciences | New and Recent Articles en-us Frontiers Feed Generator,version:1 2026-11-08T07:25:39.378+00:00 60 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17204 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17204 2026-11-02T00:00:00Z Original Research Farinaz KetabatAndy KimHamed Alizadeh SardroudBrian Frank EamesMichelle CollinsXiongbiao ChenMichael E. KellyIldiko Badea https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17612 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17612 2026-10-26T00:00:00Z Perspective Catherine Y. Lau https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17048 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17048 2026-10-20T00:00:00Z Original Research Yinjuan LiLu QiRongxia FanQian ZhangJu LiuXiaoqiang ChengXinghe Wang 0.05 and were not used for confirmatory inference. These findings are consistent with, but do not establish, a predominant pulmonary contribution to systemic exposure after nebulization. Both formulations were well tolerated, and no serious adverse events were reported.ConclusionThe test and reference budesonide inhalation suspension formulations were bioequivalent under both non-block and charcoal-block conditions. Exploratory between-cohort comparisons showed no statistically significant differences in Cmax, AUC0-t, or AUC0-inf based on nominal P values. The charcoal-related findings are consistent with, but do not establish, a predominant pulmonary contribution to systemic exposure after nebulization and should be interpreted cautiously because the conditions were evaluated in separate cohorts. Overall, the two studies provide supportive pharmacokinetic evidence for the evaluation of generic nebulized budesonide products.Trial RegistrationClinical Trial Registration: Drug Clinical Trial Registration and Information Publicity Platform of the National Medical Products Administration of China, CTR20200344 and CTR20201473 (http://www.chinadrugtrials.org.cn/); Chinese Clinical Trial Registry, ChiCTR2000035173 (https://www.chictr.org.cn/).]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17216 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17216 2026-10-20T00:00:00Z Original Research Hyewon LeeVijay KumarSoo Jung ShinYunkwon NamSinae JangHyeon soo KimMinseok LeeGyu Yong SongEun-Kyung LimHan-Jung ChaeMinho Moon https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17560 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17560 2026-10-20T00:00:00Z Review Karolina HoffmannWeronika Faustyna PucekWiktoria SkrzypekFilip KierzkowskiPiotr RatajczakViviana MaggioManfredi RizzoMohamed El-TananiSyed Arman RabbaniBhoomendra BhongadeShakta Mani SatyamSirajunisa TalathImran Rashid RangrazeAdil Farooq WaliWalaa IbraheemYahia El-TananiSorina IspasWiesław BrylAnna Paczkowska https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16471 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16471 2026-10-09T00:00:00Z Original Research Marzieh SoheiliHamed Gilzad Kohan 0, under calibration conditions), 73% efficacy enhancement through bioavailability improvement from 22% to 40%, continued structural benefit through 5 years without plateau, and consistent treatment effects (NNT = 2) across disease severity stages. All of these predictions are contingent on the same anti-catabolic potency assumption; under in vitro–consistent potency, the predicted benefit falls below clinical significance (see Conclusions and “Re-calibration across the biologically realistic potency range”).ConclusionThis QSP model provides a mechanistic framework for examining the conditions under which glucosamine could exert disease-modifying effects in knee osteoarthritis. Critically, the model’s predicted structural benefit is contingent on optimistic assumptions about both anti-catabolic potency and oral bioavailability; under values consistent with the available in vitro and pharmacokinetic evidence, the predicted benefit at achievable joint concentrations is minimal. This dependence offers a mechanistic explanation for the inconsistent and frequently null results of independent glucosamine trials. However, the assumption that salt form determines bioavailability is challenged by recent pharmacokinetic and crystallographic evidence suggesting that commercially available glucosamine sulfate formulations may not differ fundamentally from glucosamine hydrochloride in their active moiety. Model predictions are contingent on the calibration data from industry-sponsored European trials, and should be interpreted in light of the failure of independent trials to replicate these structural benefits. This work exemplifies how Model-Informed Drug Development approaches can quantify the sensitivity of clinical outcomes to pharmacokinetic parameters, informing future trial design and dose optimization.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16205 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16205 2026-10-05T00:00:00Z Review Teong Gee ThorRana SejareXin Yi TeohAhmed Bassam FarhanSri FatmawatiSiok Yee Chan https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17336 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17336 2026-09-28T00:00:00Z Original Research Uroosa KanwalIyad Naeem MuhammadAle ZehraSyed Shaukat Ali Muttaqi ShahFalak AbroTehreem AnsariNajia RahimRabya MunawarMujahid Hussain https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17413 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17413 2026-09-22T00:00:00Z Original Research Wael Y. KhawagiOmar N. Al-SharifTariq A. Al-ZahraniSaeed Saad A. AlghamdiWadia S. AlruqaybAbdullah A. Alshehri https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17260 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.17260 2026-09-17T00:00:00Z Original Research Jinal AdhiyaAli H. ShalabyAla’A. R Al-DajaniSara R. El-MahroukCarol OlympusHeidi AhonenAyman O. S. El-KadiTony K. L. Kiang https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16879 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16879 2026-09-04T00:00:00Z Original Research Toshiyuki HiraiShunsuke HanaokaYuusuke TerakadoToshiichi SekiHiroyuki HayashiFumiyuki Watanabe https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16454 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16454 2026-09-04T00:00:00Z Review Marzieh SoheiliBehdad Gilzad KohanLeila RastegarYousef MoradiHamed Gilzad Kohan 5 studies), with many organ-model pairings unexplored. Multi-organ systems showed accelerating adoption after 2021. Economic themes were discussed qualitatively, but formal health economic analyses were absent.ConclusionMPS-digital twin integration has matured from an emerging concept into a research paradigm with demonstrated translational value. Validation practices are strong and aligned with regulatory expectations, supported by the FDA Modernization Act 2.0 and the ISTAND program’s acceptance of Liver-Chip technology. Liver-focused applications are the most mature and should serve as a template for expansion. Priority gaps include kidney, lung, and brain MPS-computational integration, multi-organ systems, and rigorous health economic analyses. Continued standardization and regulatory engagement will be essential to realize this approach’s potential.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16995 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16995 2026-09-03T00:00:00Z Review Sean Chung-Hei HoIsabelle Xin Yu LeeChang LiuMingyi YuHong Chang TanGavin Siew Wei TanYu-Chi Liu https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16787 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16787 2026-07-24T00:00:00Z Original Research Sadek AhmedRana M. ElBishbishyMohamed A. SadekOsama Saher https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16612 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16612 2026-07-16T00:00:00Z Original Research Sana AliAle ZehraFakhsheena AnjumSyed Shaukat Ali Muttaqi ShahFalak AbroSadia ShakeelMuhammad Ali 7days (AOR 1.76) were identified as predictors of DRPs; past immunization was protective (AOR 0.51). Direct cost saving was PKR 363,184 (USD1,290) over 10 months (23:1 cost ratio). Cost per DRP prevented was PKR 241 (USD 0.86), with 142% return on investment.ConclusionDRPs affected 52.3 per 100 medication orders in hospitalized children with CAIs, with dose selection DRPs predominant and 9% having serious harm potential. Pharmacist-led interventions demonstrated a 98.7% acceptance rate and 81.1% resolution of DRPs, and were associated with substantial cost savings, providing evidence for integrating clinical pharmacy services in LMICs.]]> https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16451 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16451 2026-06-25T00:00:00Z Mini Review Niranjan PandaMadhusudan MaityVijay KotraBikash Ranjan JenaDebashish GhoseGouri Sankar Jena https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16610 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16610 2026-06-25T00:00:00Z Review Esraa M. MosalamMahmoud S. AbdallahAhmed R. GardouhEman HamzaMostafa M. BahaaMahmoud NazihReham A. Al-DhelaanNoha Kamal https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16158 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16158 2026-06-05T00:00:00Z Review Gatadi SrikanthNiggula Praveen KumarBhima SrideviPadma Bhavani BorraParul ThaparAabid Wani https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16570 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16570 2026-05-11T00:00:00Z Brief Research Report Andrejs SitovsKatarina GurkinaLiga PetersoneValentyn Mohylyuk https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16026 https://www.frontierspartnerships.org/articles/10.3389/jpps.2026.16026 2026-05-08T00:00:00Z Mini Review Sameh HannaAhmad ChehadeChristina HanSusan PoelmanRavina SangheraCarolyn WhiskinAaron Sihota